Turkey’s biosimilar sector is emerging as one of the most closely watched segments within the country’s pharmaceutical industry, supported by rising healthcare expenditure, an expanding base of patients requiring biologic therapies, and strong government emphasis on reducing the cost burden of complex medicines. Turkey biosimilar market size reached USD 422.0 Million in 2025. The market is projected to reach USD 2,711.7 Million by 2034, exhibiting a growth rate (CAGR) of 22.27% during 2026-2034. As patents on major biologic drugs continue to expire and Turkey’s healthcare system seeks more affordable treatment alternatives, biosimilars are increasingly positioned as a critical lever for expanding patient access to advanced therapies across oncology, autoimmune, and chronic disease categories.

How AI is Reshaping the Future of Turkey Biosimilar Market?

• AI-Driven Drug Development: Pharmaceutical companies operating in Turkey are increasingly applying machine learning models to accelerate biosimilar development timelines, particularly in protein characterization and analytical similarity testing required for regulatory approval.
• Predictive Pharmacovigilance: AI-powered monitoring systems are helping manufacturers and health authorities track adverse event patterns more efficiently, supporting faster safety signal detection across biosimilar product lines.
• Manufacturing Process Optimization: Machine learning algorithms are being deployed in bioreactor monitoring and quality control, helping manufacturers maintain batch-to-batch consistency, a critical requirement for biosimilar regulatory compliance.
• AI-Enabled Market Access Analytics: Companies are using predictive analytics to identify prescribing patterns and forecast demand across public and private healthcare channels, improving supply chain planning for biosimilar rollouts.
• Digital Health Integration: AI-supported electronic health record systems are helping physicians identify patients eligible for biosimilar switching, supporting broader adoption across Turkey’s public healthcare network.

Grab a sample PDF of this report: https://www.imarcgroup.com/turkey-biosimilar-market/requestsample

Turkey Biosimilar Market Trends & Drivers

Turkey’s biosimilar market is benefiting significantly from the structure of its public healthcare financing system, where the Social Security Institution (SGK) plays a central role in determining reimbursement and procurement policies. SGK’s pricing frameworks have consistently favored biosimilar uptake over originator biologics in several therapeutic categories, encouraging both public hospitals and private providers to prioritize biosimilar prescriptions where clinically appropriate. This reimbursement-driven substitution model has made Turkey one of the more receptive biosimilar markets within the broader Europe, Middle East, and Africa region.

Rising prevalence of chronic and autoimmune conditions is also a significant driver of market expansion. Turkey’s growing burden of conditions such as rheumatoid arthritis, psoriasis, inflammatory bowel disease, and various cancers has increased demand for biologic therapies, and biosimilars are increasingly filling this gap by offering comparable clinical efficacy at a reduced cost. This is particularly important given Turkey’s large population base and the pressure on public healthcare budgets to manage high-cost specialty medicines sustainably.

Domestic manufacturing capability is another important factor shaping the market’s trajectory. Turkish pharmaceutical companies have been investing in local biosimilar production facilities, reducing reliance on imported biologics and supporting the government’s broader localization agenda within the pharmaceutical sector. These investments are being reinforced by regulatory alignment with European Medicines Agency guidelines, which has helped Turkish-manufactured biosimilars gain credibility both domestically and in select export markets across the Middle East, Central Asia, and North Africa.

Turkey Biosimilar Industry Segmentation

The market report offers a comprehensive analysis of the segments, highlighting those with the largest Turkey biosimilar market share. It includes detailed coverage across the following segments.

The report has segmented the market into the following categories:

Product Type Insights:

• Monoclonal Antibodies
• Recombinant Human Insulin
• Recombinant Growth Hormone
• Erythropoietin
• Interferon
• Others

Application Insights:

• Oncology
• Autoimmune Diseases
• Blood Disorders
• Growth Hormone Deficiency
• Chronic and Other Conditions

Distribution Channel Insights:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Regional Insights:

• Istanbul
• Ankara
• Izmir
• Bursa
• Others

Competitive Landscape

The competitive landscape of the industry has also been examined along with the profiles of the key players operating in Turkey’s biosimilar manufacturing and distribution sector.

Recent News and Developments in Turkey Biosimilar Market

• February 2024: A leading Turkish pharmaceutical manufacturer announced the expansion of its biologics production facility in Istanbul, aimed at increasing domestic capacity for monoclonal antibody biosimilars.
• September 2024: Turkey’s Social Security Institution updated its reimbursement guidelines to further encourage biosimilar substitution across select oncology and autoimmune treatment categories within public hospitals.
• May 2025: A Turkish biopharmaceutical company entered into a licensing agreement with a European biosimilar developer to co-produce insulin biosimilars for both domestic distribution and regional export.
• January 2026: The Turkish Medicines and Medical Devices Agency introduced updated regulatory guidance aligning local biosimilar approval pathways more closely with international analytical similarity standards, aimed at streamlining market entry for new products.

Note: If you require specific details, data, or insights that are not currently included in the scope of this report, we are happy to accommodate your request. As part of our customization service, we will gather and provide the additional information you need, tailored to your specific requirements. Please let us know your exact needs, and we will ensure the report is updated accordingly to meet your expectations.

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No: (D) +91 120 433 0800
United States: +1-201971-6302